Pharma: Other News To Note
Wednesday, December 19, 2012
Merck & Co. Inc., of Whitehouse Station, N.J., and GE Healthcare, of Princeton, N.J., inked a clinical study collaboration, license and supply agreement for the use of [18F]Flutemetamol, an investigational positron emission tomography imaging agent, to support Merck's development of MK-8931, an oral, beta-amyloid precursor protein site cleaving enzyme inhibitor in development for Alzheimer's disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.